Back to Search Start Over

Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.

Authors :
Krishnan JK
Ancy KM
Oromendia C
Hoffman KL
Easthausen I
Leidy NK
Han MK
Bowler RP
Christenson SA
Couper DJ
Criner GJ
Curtis JL
Dransfield MT
Hansel NN
Iyer AS
Paine Iii R
Peters SP
Wedzicha JA
Woodruff PG
Ballman KV
Martinez FJ
Source :
Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2022 Apr 29; Vol. 9 (2), pp. 195-208.
Publication Year :
2022

Abstract

Rationale: It has been suggested that patients with chronic obstructive pulmonary disease (COPD) experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.<br />Objectives: To compare standard deviation with other statistical measures of symptom variability and identify characteristics of individuals with higher symptom variability.<br />Methods: Individuals in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained 4 weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during 4 follow-up weeks was explored.<br />Measurements and Main Results: Diary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week 4 was 0.32. Higher variability participants had higher St George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 versus 39.6 ± 21.5, p =.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and health care resource utilization-defined exacerbations.<br />Conclusions: WS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.<br /> (JCOPDF © 2022.)

Details

Language :
English
ISSN :
2372-952X
Volume :
9
Issue :
2
Database :
MEDLINE
Journal :
Chronic obstructive pulmonary diseases (Miami, Fla.)
Publication Type :
Academic Journal
Accession number :
35403414
Full Text :
https://doi.org/10.15326/jcopdf.2021.0263